Immunology
The Immunology Department at St James’s hospital runs a number of both investigator-led and industry centered drug trials in Immunology.
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| CDZ | An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) | Clinical Trial (NCT02435173) (2014-003876-22) | Novartis | Commercial: Industry |
| CDZ OLE | An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) | Clinical Trial (NCT02859727)(2016-000468-41) | Novartis | Commercial: Industry |
| HyQvia | Non-interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects treated with HyQvia | Observational-non invasive (NCT01034969) | Baxalta | Commercial: Industry |
| IOS registry | Icatibant Outcome Survey (IOS) registry protocol | Observational-non invasive (NCT01034969) | Shire | Commercial: Industry |
| ABT in Urticaria | Health through attention based training (ABT) for patients in SJH with urticaria | Observational-non invasive | Non-commercial: Academic |